• Home
  • News
  • NIDA study compares OUD Tx medications

NIDA study compares OUD Tx medications

December 14, 2017 4:22 PM | Deleted user

December 13, 2017

Dear Partners:

nidamed_FB_Tw_hands_prescription-bottle-11.28..jpgWe are excited to share the findings of a new study conducted within the NIDA Clinical Trials Network, which suggests that a buprenorphine/naloxone combination and an extended release naltrexone formulation show similar patient outcomes in the treatment of opioid use disorder (OUD) once the medications are initiated. As hypothesized, it was more difficult for active opioid users to initiate treatment with naltrexone, since using this drug requires complete detoxification.

"The good news is we filled the evidentiary void, and also learned that, for those who were able to initiate treatment, the outcomes were essentially identical, as were adverse events," said John Rotrosen, M.D., the study lead investigator. "This gives patients the freedom to choose a treatment approach that best suits their lifestyle, goals, and wishes."

More on OUD Treatment
Visit the NIDAMED Treatment Information page for other OUD treatment study findings and for resources on opioid and drug addiction treatment for both clinicians and patients.

Share the News!
Please share this message with members, peers, and colleagues and visit NIDAMED for updates on on the rapidly evolving field of opioid treatment. If you would like sample promotional material (e.g., social media messages, graphics, or brief text) to share this information, please contact the NIDAMED coordinator, Michelle Corbin.

With kind regards,


Follow NIDA on Twitter and Facebook.

Contact WISAM

563 Carter Court, Suite B
Kimberly, WI 54136

Donate Today!

Help fund WISAM
WISAM is funded in part by generous donations from patrons such as yourself.  Click here to make your donation today.  Your donation is tax deductable.

Copyright © 2018 WISAM All rights reserved.  | Terms of Use | Privacy Policy

Powered by Wild Apricot Membership Software